Sakura Iizumi

Sakura Iizumi

Auto-generated profile, based on publicly available information

Sakura Iizumi

AstraZeneca K.K. Tokyo Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2018 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
SISakura Iizumi
Sakura Iizumi
Atsuo TakashimaAtsuo Takashima
Atsuo Takashima
KSKentaro Sakamaki
Kentaro Sakamaki
SMSatoshi Morita
Satoshi Morita
NBNarikazu Boku
Narikazu Boku

2 December 2019 in Cancer Science
Verified
Journal Article
Open access
PDF file
TKTakafumi Koyama
Takafumi Koyama
TSToshio Shimizu
Toshio Shimizu
SISatoru Iwasa
Satoru Iwasa
YFYutaka Fujiwara
Yutaka Fujiwara
SKShunsuke Kondo
Shunsuke Kondo
NYNoboru Yamamoto
Noboru Yamamoto
Fibroblast growth factor receptors (FGFR) are a family of transmembrane receptor tyrosine kinases involved in regulating cellular processes. FGFR mutations are implicated in oncogenesis, representing therapeutic potential in the form of FGFR inhibitors. This phase I, first‐in‐human study in Japan evaluated safety and tolerability of E7090, a potent selective FGFR1‐3 inhibitor, in patients with advanced solid tumors. Dose escalation (daily oral dose of 1‐180 mg) was carried out to assess dose‐limiting toxicity (DLT), maximum tolerated dose, and pharmacokinetics. Pharmacodynamic markers (serum phosphate, fibroblast growth factor 23, and 1,25‐(OH)2‐vitamin D) were also evaluated. A total of 24 patients refractory to standard therapy or for whom no appropriate treatment was available were enrolled. No DLT were observed up to the 140‐mg dose; one patient in the 180‐mg cohort experienced a DLT (increased aspartate aminotransferase/alanine aminotransferase, grade 3). The maximum tolerated dose was not reached. Dose‐dependent increases in the maximum concentration and area under the curve from time 0 to the last measurable concentration were observed up to 180 mg. Dose‐dependent increases were observed in all pharmacodynamic markers and plateaued at 100‐140 mg, indicating sufficient FGFR pathway inhibition at doses ≥100 mg. In conclusion, E7090 showed a manageable safety profile with no DLT at doses ≤140 mg. Maximum tolerated dose was not determined. The recommended dose for the follow‐up expansion part, restricted to patients with tumors harboring FGFR alterations, was determined as 140 mg, once daily.

16 March 2021 in Cancer Science
Verified
Journal Article
Open access
PDF file
KIKoji Izutsu
Koji Izutsu
KAKiyoshi Ando
Kiyoshi Ando
DEDaisuke Ennishi
Daisuke Ennishi
HSHirohiko Shibayama
Hirohiko Shibayama
JSJunji Suzumiya
Junji Suzumiya
HNHirokazu Nagai
Hirokazu Nagai
This multicenter, open‐label, phase I study assessed the safety and antitumor activity of acalabrutinib in Japanese patients with relapsed/refractory (r/r) B‐cell malignancies. Parts 1 (dose confirmation) and 2 (dose expansion) of this three‐part study are reported. Treatment was a single dose of 100 mg acalabrutinib (day 1), followed by a washout period and then twice daily 100 mg acalabrutinib in part 1, or twice daily 100 mg acalabrutinib in part 2. Patients from parts 1 and 2 with r/r chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and r/r mantle cell lymphoma (MCL) were assessed as r/r CLL/SLL and r/r MCL cohorts, respectively. Twenty‐five patients received treatment (part 1, n = 6). Median age was 71.0 years. Nine (one patient from part 1) and 13 (two patients from part 1) patients were included in the r/r CLL/SLL and r/r MCL cohorts, respectively. Treatment‐related adverse events (AEs) occurred in 88% of patients (grade ≥3, 36%); the most common were headache (28%) and purpura (24%), both grade 1/2. No AEs resulted in treatment discontinuation or death. Median duration of treatment was 31, 20, and 7 months for part 1, r/r CLL/SLL cohort, and r/r MCL cohort, respectively. Overall response rate (ORR) was 89% and 62% for the r/r CLL/SLL and r/r MCL cohorts, respectively. The median progression‐free survival (PFS) was not reached for the r/r CLL/SLL cohort and was 7 months for the r/r MCL cohort. Acalabrutinib (100 mg twice daily) was generally safe and well‐tolerated in adult Japanese patients with B‐cell malignancies.

1 July 2019 in Practical Radiation Oncology
Verified
Journal Article
Closed access
KTKashihara Tairo
Kashihara Tairo
NMNaoya Murakami
Naoya Murakami
SISakura Iizumi
Sakura Iizumi
YSYasunari Sakamoto
Yasunari Sakamoto
SNSatoshi Nakamura
Satoshi Nakamura
JIJun Itami
Jun Itami

20 July 2017 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
SISakura Iizumi
Sakura Iizumi
Atsuo TakashimaAtsuo Takashima
Atsuo Takashima
YNYukiya Narita
Yukiya Narita
MTMasahiro Tajika
Masahiro Tajika
KMKei Muro
Kei Muro
NBNarikazu Boku
Narikazu Boku

5 June 2018 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Open access
PDF file
SISakura Iizumi
Sakura Iizumi
Akihiko ShimomuraAkihiko Shimomura
Akihiko Shimomura
TSTatsunori Shimoi
Tatsunori Shimoi
KSKazuki Sudo
Kazuki Sudo
ENEmi Noguchi
Emi Noguchi
KTKenji Tamura
Kenji Tamura
We conducted a retrospective study to assess the outcomes of capecitabine for advanced breast cancer (ABC) after perioperative fluoropyrimidines (FPs).